Patau sindrom by Vida Čulić et al.
27
 Paediatr Croat. 2016;60:27-30




Vida Čulić1, Branka Polić2, Silvana Mišković3, Slavica Dragišić Ivulić4, Vanda Zitko5, 
Tatijana Sipalo1, Jasminka Pavelić6
Genetic syndromes caused by chromosomal aberrations involve a recognizable pattern of multiple congenital anomalies with 
 increased neonatal and infant mortality, making care challenging for the family, primary care practitioners, and specialists. About 
28% of children born with trisomy 13 die during the fi rst week of life. The median life expectancy is about 2.5 days. We present a 
12-year-old girl, the longest living patient with Patau syndrome in Croatia, followed-up from the birth until the age of 12 years. The 
conventional nonintervention approach has been revised and we suggest changing the traditional view of the condition.
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INTRODUCTION
Patau syndrome (trisomy 13) is one of the most common 
chromosomal anomalies clinically characterized by the pre-
sence of numerous malformations with a limited survival 
rate for most cases. It is the third most frequent chromo-
somal trisomy with estimated incidence of about 1/8000-
12,000 births. Spontaneous abortions, after 12 weeks of ges-
tation, are 100 times more often caused by trisomy 13 than 
by any other condition. Between 12 weeks of gestation and 
term, 49% (95% CI: 29-73%) of pregnancies diagnosed with 
trisomy 13 are estimated to end with miscarriage or still-
birth (1, 2).
Compared to the general neonatal mortality rate, the esti-
mated mortality rate for trisomy 13 is about 50 times higher 
(1). Trisomy 13 is cytogenetically classifi ed as a full trisomy 
(47,XY,+13) due to the nondisjunction at meiosis I or II, or at 
mitosis (mosaicism) and partial trisomy due to transloca-
tions. Patau syndrome due to translocations can be inherit-
ed if one of the parents carries a balanced rearrangement of 
genetic material between chromosome 13 and another 
chromosome. Robertsonian translocations may involve two 
chromosome 13 /46,XX,t(13;13)/, or chromosome 13 and 
another acrocentric (14,15,21,22). Robertsonian transloca-
tion 13:14 is the most common translocation of this type in 
the population. Robertsonian translocation 13;14 in about 
60% of cases occurs de novo, in 25% is maternally and in 
15% paternally inherited. In most cases, translocation 13;13 
arises de novo because one of the parents carries a 100% risk 
of Patau syndrome in the off spring. The mean maternal age 
is increased for free trisomy 13 (1, 2). Twenty-eight percent 
of newborns with Patau syndrome die within the fi rst week 
of life, 44% in the fi rst month, and 86% by one year of age. 
The median survival age is 2.5 days, and only a small num-
ber of cases experience puberty age. Most infants with Pa-
tau syndrome have a high mortality: 69% from cardiopul-
monary failure, 13% from congenital heart defects, and 4% 
from pneumonia (1, 2). Newborns with Patau syndrome 
present at birth with low birth weight and often with intra-
uterine growth retardation, one umbilical artery, prolonged 
persistence of fetal hemoglobin, doubled organs, micro-
cephaly, microphthalmia, arrhinencephalia, bilateral cleft lip 
and palate, postaxial hexadactyly, and a wide spectrum of 
anomalies of the heart and great vessels. About 4/5 of cases 
reveal renal anomalies and a variety of muscular and skele-
tal anomalies. Most of these patients are blind and deaf, 
with epilepsy and severe developmental delays (1).
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CASE REPORT
We present a 12-year-old girl, the longest living patient with 
Patau syndrome in Croatia. She is the second child of 
healthy young parents who had a child with Edwards syn-
drome (full trisomy 18 with karyotype: 47,XY+18) from pre-
vious pregnancy. The child died a few days after birth. The 
parents have normal karyotypes; after genetic counseling, 
they refused prenatal diagnosis for the second pregnancy.
Our patient with Patau syndrome has a full trisomy, a tan-
dem translocation 13;13 de novo 46,XX,der(13;13)(p11.2;
p11.2). The diagnosis was confi rmed by fl uorescent in situ 
hybridization (FISH) from peripheral blood and skin culture: 
ish psu idic(13;13)(13pter13cen13p11.2::13p11.213p
su cen13qter)(D13Z1++). FISH was performed on meta-
phase chromosomes using alphoid 13 and 21 specifi c cen-
tromeric DNA probe (D13Z1/D21Z1, Kreatech). Hybridiza-
tion showed one centromeric signal on normal chromo-
some 13, and two signals on der(13;13) chromosome. The 
Robertsonian translocation (13;13) was dicentric.
Upon delivery, the newborn manifested right-sided cleft lip 
and palate, coloboma of iris on both eyes, heart defect (atri-
al septal defect II), and right double urinary channels. She 
also developed acute respiratory failure, was intubated and 
mechanically ventilated in the Pediatric Intensive Care Unit 
(PICU), and tracheotomy was done. She was successfully 
weaned from the respirator some months later and surgical 
correction of the cleft lip and palate was performed. At the 
age of 3 years, decannulation was fi nally performed.
Today, she is 12-years old; she does not walk or speak, and is 
prone to recurrent bronchopneumonia because of which is 
often hospitalized (Figure 1). During her long hospitaliza-
tion, her mother was educated for home care, which is pri-
marily related to changing and hygiene of the cannula set, 
gauge feeding, aspiration of secretions, inhalation tech-
nique and use of oxygen through a mask. In order to achieve 
a satisfactory clinical condition of the girl, she was placed on 
home care with her family and since then has been in home 
conditions. After some time, she developed symptomatic 
epilepsy. In the process of genetic counseling, the parents 
were informed on the possibility of prenatal diagnosis or 
preimplantation diagnosis, however, they were not ready 
for new pregnancy.
All procedures were approved by the local Ethics Commit-
tee and carried out with full understanding and written 
consent of the parents.
DISCUSSION
Cases of children diagnosed with Patau syndrome or Ed-
wards syndrome who lived longer than the average life ex-
pectancy for these conditions are rarely described in the 
literature (2-4). Considering the real life experience and data 
from medical literature, the question is how much eff ort, 
knowledge and material resources should be invested in 
the treatment of children with severe chromosomal abnor-
malities. There is a clear ethical rule that a doctor has a pri-
mary obligation of personal care for each patient (5).
Cases similar to our patient have been described in the lit-
erature from 1993, 2004, 2006, 2010, 2011 and 2014 (6-11). 
The intensity of delivery room care for very low birth weight 
infants with trisomy 13 or trisomy 18 varied depending on 
the timing of trisomy diagnosis. For the majority of infants, 
the plan for subsequent care was to withdraw care or to 
provide comfort care only. This practice infl uenced the tim-
ing of death and rates of survival to discharge (7, 8). The psy-
chological support off ered to the mother was, and has 
been, of great help to the development and maintenance 
of the mother-child relationship. This close relationship, 
added to the tireless maternal eff ort to provide the best 
quality of life, seems to have contributed positively to the 
long survival of the child (11). These reports support better 
prognosis of trisomies through treatment at PICU based on 
improved survival period. Educating parents about their 
child’s diagnosis and developmental outcomes is impor-
tant. Medical team has to make it clear to parents what can 
be provided, intensive or comfort management, and get 
informed consent from them (12).
In our case, medical decision on the intervention was sup-
ported by the choice of the parents who were eager for FIGURE 1. A girl suff ering from Patau syndrome at the age of 7 years.
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their child to survive although being faced with her severe 
disability. Based on the experience, we think that each pa-
tient is an individual case and the fi nal decision should be 
made respecting the family’s choice. Considering that par-
ents usually hope to spend some weeks, months, or maybe 
a few years with their child, we generally advocate intensive 
treatment for children with trisomies regardless of the pos-
sible complications of treatment, their disability and shorter 
life expectancy (12-15).
All measures and actions we take must be directed to sup-
port and care of children with chromosomal aberrations 
and their parents in order to benefi t the lives regardless of 
how long they would be. The primary and tertiary care con-
sultants who are able to provide knowledge and sensitive 
supportive care for children with trisomy 13 and trisomy 18 
and their families, are performing a service of signifi cant 
benefi t. The fi rst study which investigated the eff ect of in-
tensive management including optional cardiac surgery on 
the survival of patients with trisomy 13 or trisomy 18 with 
heart defect (patent ductus arteriosus) showed signifi cant 
improvement in survival through both pharmacological in-
tervention and cardiac surgery. The patients with trisomy 13 
may have a high probability of long-term survival if they 
survive over 60 days after birth. One of the major factors for 
long-term survival of patients with trisomy 13 is active re-
suscitation which follows immediately after birth, as well as 
various surgical treatments such as tracheotomy and cardi-
ac surgery (14).
In conclusion, Patau syndrome involves a recognizable pat-
tern of multiple congenital anomalies with increased neo-
natal and infant mortality and signifi cant intellectual dis-
ability in older children, making care challenging for the 
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S A Ž E T A K
Patau sindrom
V. Čulić, B. Polić, S. Mišković, S. Dragišić Ivulić, V. Zitko, T. Sipalo, J. Pavelić
Genetski sindromi uzrokovani kromosomnim aberacijama uključuju prepoznatljivi obrazac višestrukih prirođenih anomalija s pove-
ćanom smrtnošću novorođenčadi i dojenčadi, što skrb za njih čini teškom za obitelj, liječnike primarne zdravstvene skrbi i specijaliste. 
Oko 28% djece rođene s trisomijom 13 umire tijekom prvog tjedna života. Srednje očekivano trajanje života je oko 2,5 dana. Prikazu-
jemo 12-godišnju djevojčicu, najduže živuću bolesnicu s Patauovim sindromom u Hrvatskoj, koju pratimo od rođenja do njezine 
sadašnje dobi od 12 godina. Konvencionalni pristup zasnovan na izostanku intervencije doživio je reviziju, a mi predlažemo promje-
nu tradicionalnog pogleda na ovo stanje.
Ključne riječi: Patauov sindrom; očekivano trajanje života; kromosomne anomalije
